Equities analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce sales of $33.63 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Heron Therapeutics’ earnings. The highest sales estimate is $37.20 million and the lowest is $30.00 million. Heron Therapeutics reported sales of $19.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 69.9%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Heron Therapeutics will report full-year sales of $130.42 million for the current year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts expect that the business will report sales of $197.38 million, with estimates ranging from $150.00 million to $253.70 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The business had revenue of $36.66 million for the quarter, compared to the consensus estimate of $31.04 million.

A number of research analysts have recently weighed in on HRTX shares. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. Northland Securities reiterated a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th. Evercore ISI reiterated a “buy” rating and set a $75.00 price target on shares of Heron Therapeutics in a report on Tuesday, August 13th. Finally, ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Hold” and an average target price of $52.67.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Heron Therapeutics by 5.5% in the first quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock valued at $207,101,000 after buying an additional 439,044 shares in the last quarter. Vanguard Group Inc. raised its position in Heron Therapeutics by 5.2% during the second quarter. Vanguard Group Inc. now owns 6,744,858 shares of the biotechnology company’s stock valued at $125,387,000 after purchasing an additional 330,351 shares in the last quarter. BlackRock Inc. raised its position in Heron Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 4,901,392 shares of the biotechnology company’s stock valued at $91,116,000 after purchasing an additional 42,657 shares in the last quarter. Clearbridge Investments LLC raised its position in Heron Therapeutics by 153.4% during the first quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after purchasing an additional 1,320,025 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Heron Therapeutics by 60.2% during the second quarter. JPMorgan Chase & Co. now owns 1,425,517 shares of the biotechnology company’s stock valued at $26,274,000 after purchasing an additional 535,821 shares in the last quarter.

Shares of HRTX stock traded down $0.23 on Monday, reaching $20.51. 846,271 shares of the company’s stock traded hands, compared to its average volume of 947,332. Heron Therapeutics has a 12-month low of $15.68 and a 12-month high of $35.52. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.70 and a current ratio of 4.01. The company has a market capitalization of $1.64 billion, a P/E ratio of -8.41 and a beta of 1.47. The business’s 50 day moving average price is $17.75 and its two-hundred day moving average price is $20.27.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Swap

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.